We are passionate about science
Our Pipeline
Touch the icons to find out more
We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.
Compound
Mechanism of Action
Target Indication
Status
Daridorexant
Dual orexin receptor antagonist
Insomnia
Commercially available in the US, Germany, Italy, Switzerland, Spain, UK, France, and Canada; Approved in the EU; Phase 2 in pediatric insomnia – recruiting
Compound
Mechanism of Action
Target Indication
Status
Aprocitentan
Dual endothelin receptor antagonist
Resistant hypertension management
Approved in the US, product availability planned for Q4 2024 Approved in the EU. Marketing authorization applications for the UK, Canada, and Switzerland in preparation
Compound
Mechanism of Action
Target Indication
Status
Lucerastat
Glucosylceramide synthase inhibitor
Fabry disease
Phase 3 primary endpoint not met, open-label extension study ongoing
Compound
Mechanism of Action
Target Indication
Status
Selatogrel
P2Y12 receptor antagonist
Suspected acute myocardial infarction
Viatris and Idorsia have a global research and development collaboration agreement for selatogrel. Phase 3 recruiting
Compound
Mechanism of Action
Target Indication
Status
Cenerimod
S1P1 receptor modulator
Systemic lupus erythematosus
Viatris and Idorsia have a global research and development collaboration agreement for cenerimod. Phase 3 recruiting
Compound
Mechanism of Action
Target Indication
IDOR-1117-2520
Undisclosed
Immune-mediated disorders
Compound
Mechanism of Action
Target Indication
Status
ACT-1004-1239
ACKR3 / CXCR7 antagonist
Multiple sclerosis and other demyelinating diseases
Phase 2 in preparation
Compound
Target Indication
Mechanism of action
IDOR-1134-2831
Clostridium difficile infection
Synthetic glycan vaccine
Compound
Target Indication
Status
ACT-777991
Vitiligo
Phase 2 in preparation
Compound
Mechanism of Action
Target Indication
Status
Sinbaglustat
GBA2/GCS inhibitor
Rare lysosomal storage disorders
Phase 1 complete
1
receptor antagonist
12
Status
Phase 1
Status
Phase 1 ongoing
Mechanism of action
CXCR3 antagonist
Compound
Mechanism of Action
Target Indication
Status
IDO-090
Synthetic glycan vaccine
Clostridium difficile infection
Phase 1 in preparation
Partner-led portfolio
Idorsia-led portfolio
Compound
Mechanism of Action
Target Indication
Status
Daridorexant
Dual orexin receptor antagonist
Insomnia
Nxera Pharma has a license to develop and commercialize for Asia Pacific (ex-China) NDA submitted in Japan Simcere has a license to develop and commercialize for Greater China region Approved for the treatment of insomnia in Hong-Kong NDA submitted in Greater China Idorsia supports a clinical study sponsored by the US Department of Defense (DOD) to develop new therapies to treat posttraumatic stress disorder (PTSD). Phase 2 ongoing
Compound
Mechanism of Action
Target Indication
Status
Daridorexant
Dual orexin receptor antagonist
Insomnia
Commercially available in the US, Germany, Italy, Switzerland, Spain, UK, France, and Canada Approved in the EU Phase 2 in pediatric insomnia – recruiting
Compound
Mechanism of Action
Target Indication
Status
ACT-1002-4391
EP2 / EP4 receptor antagonist
Immuno-oncology
Owkin has a global license to develop and commercialize. Phase 1 in preparation
Compound
Mechanism of Action
Target Indication
Status
ACT-709478
T-type calcium channel blocker
Epileptic encephalopathy with continuous spikeand-wave during sleep (CSCW)
Neurocrine Biosciences has the global license to develop and commercialize. Phase 2 OLE study ongoing
